Literature DB >> 8053936

Characterization of illudin S sensitivity in DNA repair-deficient Chinese hamster cells. Unusually high sensitivity of ERCC2 and ERCC3 DNA helicase-deficient mutants in comparison to other chemotherapeutic agents.

M J Kelner1, T C McMorris, L Estes, M Rutherford, M Montoya, J Goldstein, K Samson, R Starr, R Taetle.   

Abstract

Illudins, novel natural products with a structure unrelated to any other known chemical, display potent in vitro and in vivo anti-cancer activity against even multi-drug resistant tumors, and are metabolically activated to an unstable intermediate that binds to DNA. The DNA damage produced by illudins, however, appears to differ from that of other known DNA damaging toxins. The sensitivity pattern of the various UV-sensitive cell lines differs from previously studied DNA cross-linking agents. Normally, the ERCC1- (excision repair cross complementing) and ERCC4-deficient cell lines are most sensitive to DNA cross-linking agents, with ERCC2-, ERCC3- and ERCC5-deficient cell lines having minimal sensitivity. With illudins the pattern is reversed, with ERCC2 and ERCC3 being the most sensitive. The sensitivity to illudins in complementation groups 1 through 3 is due to a deficiency of the ERCC1-3 gene products, as cellular drug accumulation studies revealed no differences in transport capacity or total drug accumulation. Also, a transgenic cell line in which ERCC2 activity was expressed through an expression vector regained its relative resistance to the illudins. The EM9 cell line, which displays sensitivity to monoadduct producing chemicals, was not sensitive. Thus, excision repair is involved in repair of illudin-induced damage and, unlike other anti-cancer agents, the involvement of ERCC2 and ERCC3 helicases is critical for repair to occur. The requirement for ERCC2 and ERCC3, combined with the finding that ERCC1 but not ERCC2 is upregulated in drug-resistant tumors, may explain the efficacy of illudins against drug-resistant tumors. The inhibition of DNA synthesis in cells within minutes after exposure to illudins at nanomolar concentrations may be related to the finding that the ERCC3 gene product is actually the p89 helicase component of the BTF2 (TFII) basic transcription factor and the high sensitivity of ERCC3-deficient cells to illudins.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8053936     DOI: 10.1016/0006-2952(94)90113-9

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  12 in total

1.  Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia.

Authors:  F Giles; J Cortes; G Garcia-Manero; S Kornblau; E Estey; M Kwari; A Murgo; H Kantarjian
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

2.  A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with advanced non-small cell cancer previously treated with chemotherapy.

Authors:  J E Dowell; D H Johnson; J S Rogers; Y Shyr; N McCullough; P Krozely; R F DeVore
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

3.  Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents.

Authors:  M J Kelner; T C McMorris; L Estes; W Wang; K M Samson; R Taetle
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

4.  Improved efficacy of acylfulvene in colon cancer cells when combined with a nuclear excision repair inhibitor.

Authors:  Paul M van Midwoud; Shana J Sturla
Journal:  Chem Res Toxicol       Date:  2013-11-05       Impact factor: 3.739

5.  Quantification of acylfulvene- and illudin S-DNA adducts in cells with variable bioactivation capacities.

Authors:  Kathryn E Pietsch; Paul M van Midwoud; Peter W Villalta; Shana J Sturla
Journal:  Chem Res Toxicol       Date:  2012-12-19       Impact factor: 3.739

6.  A phase II study of Irofulven (MGI 114) in patients with stage IV melanoma.

Authors:  A Scott Pierson; Peter Gibbs; Jon Richards; Paul Russ; S Gail Eckhardt; Rene Gonzalez
Journal:  Invest New Drugs       Date:  2002-08       Impact factor: 3.850

7.  Enhanced antitumor activity of irofulven in combination with antimitotic agents.

Authors:  Michael J Kelner; Trevor C McMorris; Rafael J Rojas; Nicole A Trani; Tami R Velasco; Leita A Estes; Pharnuk Suthipinijtham
Journal:  Invest New Drugs       Date:  2002-08       Impact factor: 3.850

8.  Synergy of Irofulven in combination with various anti-metabolites, enzyme inhibitors, and miscellaneous agents in MV522 lung carcinoma cells: marked interaction with gemcitabine and 5-fluorouracil.

Authors:  Michael J Kelner; Trevor C McMorris; Rafael J Rojas; Leita A Estes; Pharnuk Suthipinijtham
Journal:  Invest New Drugs       Date:  2008-01-29       Impact factor: 3.850

9.  DNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine.

Authors:  Alessia Stornetta; Maike Zimmermann; George D Cimino; Paul T Henderson; Shana J Sturla
Journal:  Chem Res Toxicol       Date:  2017-01-03       Impact factor: 3.739

10.  A Chemical Proteomic Analysis of Illudin-Interacting Proteins.

Authors:  Philipp Le; Matthew B Nodwell; Jürgen Eirich; Stephan A Sieber
Journal:  Chemistry       Date:  2019-09-03       Impact factor: 5.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.